Skip to content

Mannitol

Published: July 26, 2026Updated: July 26, 2026

Mannitol is an osmotic diuretic that promotes water excretion through the kidneys while helping maintain electrolyte balance, primarily used to reduce elevated intracranial and intra pressure.

Quick summary

Mannitol is an osmotic diuretic used to reduce brain and eye pressure and prevent kidney injury by drawing excess fluid through the kidneys.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

ATC
A06AD16
RxNorm
6628
Generic
Mannitol
Class
atc-a06
Brands
Osmitrol, Bronchitol
Availability
rx
Lactation
unknown
Routes
topical
Forms
injection, powder, cream, solution
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Dosage and administration

adult (standard)injection
Usual dose
1-2 g/kg as single dose
Maximum
consult physician
Frequency
as needed
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
pediatric (standard)injection
Usual dose
0.5-1 g/kg over 30-60 minutes
Maximum
consult physician
Frequency
as needed
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
geriatric (standard)injection
Usual dose
0.5-1 g/kg over 30-60 minutes
Maximum
consult physician
Frequency
as needed
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard

Overdose information

Important overdose information
Toxic dose: Single dose exceeding 2g/kg may cause serious toxicity, particularly in patients with renal impairment
Chronic overdose: Prolonged use or cumulative dosing without proper monitoring can lead to electrolyte imbalances and fluid overload
Immediate actions
Discontinue mannitol infusion immediately, assess vital signs and neurological status, obtain intravenous access, check renal function and electrolytes
Antidote
No specific antidote exists(Supportive care is primary treatment; mannitol is rapidly eliminated by renal dialysis in severe cases)
Poison Control: 1-800-222-1222

Special Populations

10 groups
⚠

pregnancy

first trimester
caution
FDA Category
C
Dose Adjustment

avoid if possible

Key Recommendations

Use only if benefits outweigh risks. Limited data available on safety in first trimester.

Monitor

regular fetal monitoring

Use with caution and monitor for adverse effects.

⚠

pregnancy

second trimester
caution
FDA Category
C
Dose Adjustment

use lowest effective dose

Key Recommendations

Use only if clearly needed. Monitor fluid balance closely.

Monitor

regular fetal monitoring and maternal fluid status

Use with caution and monitor for adverse effects.

⚠

pregnancy

third trimester
caution
FDA Category
C
Dose Adjustment

use lowest effective dose

Key Recommendations

Use only if benefits outweigh risks. Monitor for fluid overload.

Monitor

regular fetal monitoring, maternal fluid balance, blood pressure

Use with caution and monitor for adverse effects.

⚠

lactation

breastfeeding
caution
FDA Category
N
Dose Adjustment

monitor infant

Key Recommendations

Mannitol is excreted in breast milk in small amounts. Use with caution and monitor infant.

Monitor

observe infant for signs of dehydration or electrolyte changes

Use with caution and monitor for adverse effects.

⚠

geriatric

elderly
caution
FDA Category
N
Dose Adjustment

reduce dose, monitor renal function

Key Recommendations

Start with lower doses. Monitor renal function and fluid balance closely.

Monitor

renal function tests, fluid balance, electrolytes

Use with caution and monitor for adverse effects.

⚠

pediatric_age

children
caution
FDA Category
N
Dose Adjustment

weight-based dosing

Key Recommendations

Use under close medical supervision. Dosing is weight-based.

Monitor

fluid balance, electrolytes, renal function

Use with caution and monitor for adverse effects.

⚠

pediatric_age

infants
caution
FDA Category
N
Dose Adjustment

reduce dose, use cautiously

Key Recommendations

Limited data. Use only in hospital setting with close monitoring.

Monitor

intensive fluid and electrolyte monitoring

Use with caution and monitor for adverse effects.

✗

renal_impairment

severe
contraindicated
FDA Category
N
Dose Adjustment

avoid use

Key Recommendations

Contraindicated in severe renal impairment, anuria, pulmonary edema, congestive heart failure.

Monitor

renal function must be monitored before and during treatment

Use of this medication in this population requires careful consideration of risks and benefits.

⚠

renal_impairment

mild to moderate
caution
FDA Category
N
Dose Adjustment

reduce dose, monitor closely

Key Recommendations

Use with caution. May need dose reduction. Monitor renal function.

Monitor

renal function tests, urine output, fluid balance

Use with caution and monitor for adverse effects.

⚠

hepatic_impairment

moderate
caution
FDA Category
N
Dose Adjustment

monitor closely

Key Recommendations

Use with caution. Mannitol is not extensively metabolized by liver but monitor fluid balance.

Monitor

liver function tests, fluid balance, electrolytes

Use with caution and monitor for adverse effects.

Statistics and clinical data

drug_classWHO
2023

Drug class

Value:Osmotic diuretic

Classified as an osmotic diuretic under ATC code C03BA01

usageFDA
2023

Common uses

Value:Reduction of intracranial and intraocular pressure

Primary therapeutic uses in emergency and surgical settings

prescribingFDA
2023

FDA approval year

Value:1970s

Initial FDA approval for Mannitol intravenous solution

mechanismFDA
2023

Mechanism of action

Value:Osmotic diuresis

Creates osmotic gradient to draw water into renal tubules

Treatment of elevated intracranial pressure (ICP) and intracranial hypertension, reduction of intraocular pressure (IOP) during acute glaucoma attacks or eye surgery, and prevention of acute kidney injury (AKI) through forced osmotic diuresis. Also used as an osmotic laxative for constipation.

Mannitol is a small molecular weight sugar alcohol that remains largely confined to the extracellular space. When administered intravenously, it creates an osmotic gradient in the renal tubules that hinders water reabsorption and enhances excretion of sodium and chloride, thereby promoting diuresis and reducing fluid accumulation in tissues.

Administered by IV infusion only; requires adequate renal function and cardiac output to be effective. Contraindicated in severe dehydration, anuria, and pulmonary edema or congestion. Monitor serum osmolality, electrolytes, and renal function during treatment. May cause rebound increased ICP if therapy is discontinued abruptly after prolonged use.

Contraindications

Conditions and patient states where this medication should be avoided or used with caution.

Do not use (1)

ABSOLUTEhypersensitivity

Known allergy to this medication or its components

Use caution (1)

RELATIVEpregnancy

Consult healthcare provider for benefits vs risks assessment

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy